The American Society of Hematology (ASH) Annual Meeting brings together over 25,000 clinicians and scientists from around the world to discuss the latest research and advances in the blood cancer and blood disorders field. The 67th annual meeting took place December 6-9 in Orlando, Florida.
The Weill Cornell Medicine (WCM) Silver Myeloproliferative Neoplasm (MPN) Center was involved with several research studies shared throughout the conference. We are proud to highlight some of this work from ASH 2025.
Dr. Joseph Scandura, Scientific Director of the Silver MPN Center, was part of a phase 3 clinical trial evaluating rusfertide for polycythemia vera. The longer-term follow up results were presented at the conference.
Dr. Franco Castillo-Tokumori shared Weill Cornell Medicine-led research on JAK2V617F variant allele frequency (VAF) in polycythemia vera.
Research program assistant Katie Erdos was first author on research looking at outcomes of primary myelofibrosis patients treated with interferon alfa
Dr. Joseph Scandura was involved with research evaluating a combination treatment for myeloproliferative neoplasm patients with myelofibrosis.
Dr. Franco Castillo Tokumori shared results of technology developed at Weill Cornell Medicine to determine clonal fitness of MPN cells using patient samples.
Silver MPN Center research compared different prognostic models for polycythemia vera that are commonly used to guide initial treatment. Learn more from Katie Erdos.
The Weill Cornell Medicine Silver MPN Center is proud to have some of our research selected at this year’s ASH meeting in order to provide updates on the latest research, treatments, and technologies that are being developed for myeloproliferative neoplasms. We are dedicated to continuing to study and lead MPN research throughout the year in an effort to improve the lives of those impacted by MPNs.